| Purpose: 5-fuorouracil (5-FU), an efective chemotherapy drug, is commonly applied for colorectal cancer treat‑
ment. Nevertheless, its toxicity to normal tissues and the development of tumor resistance are the main obstacles to
successful cancer chemotherapy and hence, its clinical application is limited. The use of resveratrol can increase 5-FUinduced cytotoxicity and mitigate the unwanted adverse efects. This study aimed to review the potential therapeutic
efects of resveratrol in combination with 5-FU against colorectal cancer.
Conclusion: The results obtained from this systematic review demonstrated that co-administration of resveratrol
could sensitize the colorectal cancer cells to 5-FU treatment via various mechanisms, including regulation of cell cycle
distribution, oxidant, apoptosis, anti-infammatory efects
Methods: According to the PRISMA guideline, a comprehensive systematic search was carried out for the identifca‑
tion of relevant literature in four electronic databases of PubMed, Web of Science, Embase, and Scopus up to May
2021 using a pre-defned set of keywords in their titles and abstracts. We screened 282 studies in accordance with our
inclusion and exclusion criteria. Thirteen articles were fnally included in this systematic review.
Results: The in vitro fndings showed that proliferation inhibition of colorectal cancer cells in the groups treated by
5-FU was remarkably higher than the untreated groups and the co-administration of resveratrol remarkably increased
cytotoxicity induced by 5-FU. The in vivo results demonstrated a decrease in tumor growth of mice treated by 5-FU
than the untreated group and a dramatic decrease was observed following combined treatment of resveratrol and
5-FU. It was also found that 5-FU alone and combined with resveratrol could regulate the cell cycle profle of colo‑
rectal cancer cells. Moreover, this chemotherapeutic agent induced the biochemical and histopathological changes
in the cancerous cells/tissues and these alterations were synergized by resveratrol co-administration (for most of the
cases), except for the infammatory mediators. |